

Ocular Therapeutix Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 19-Nov-2014

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 6

Product Portfolio Drug Pipeline Detail..... 9

 Phase 3 Clinical..... 10

 Phase 2 Clinical..... 13

 Clinical..... 17

 Discovery..... 20

[Return to Table of Contents](#)

Ocular Therapeutix Inc

COMPANY OVERVIEW

Company Name	Ocular Therapeutix Inc
Parent Company Name	Ocular Therapeutix Inc
Website	http://www.ocutx.com/
Country	US
Number of Drugs in Active Development	4
Number of Inactive Drugs	2
Number of Patents as Owner	0
Number of Patents as Third Party	1
Number of Deals	0
Key Indications	Glaucoma, Allergic conjunctivitis, Conjunctivitis, Ocular inflammation, Ocular pain, Retinopathy, Angle closure glaucoma, Ocular hypertension, Open angle glaucoma
Key Target-based Actions	DNA gyrase inhibitor, Glucocorticoid agonist, Prostanoid receptor agonist, Topoisomerase IV inhibitor, VEGF receptor antagonist
Key Technologies	Sustained release formulation, Small molecule therapeutic, Ophthalmic gel formulation, Drug implant, Microparticle formulation, Ophthalmic formulation, PEGylated formulation, Antibiotic, Lipid, Ophthalmic drug

COMPANY PROFILE

SUMMARY

Ocular Therapeutix Inc (formerly I-Therapeutix), founded in November 2006, aims to develop and commercialize ophthalmic therapeutic products and ocular drug delivery vehicles using its hydrogel technology. In September 2009, I-Therapeutix changed its name to Ocular Therapeutix.

FINANCIAL

In July 2014, Ocular priced an IPO of 5 million shares at \$13 per share. Underwriters were granted an overallotment option to purchase up to 0.75 million additional shares. Shares were expected to be traded on the NASDAQ Global Market under the ticker symbol 'OCUL' on July 25, 2014. In August 2014, the company raised gross and net proceeds of approximately \$74.8 and \$66.5 million, respectively through the IPO of 5.75 million shares including the full exercise of the over-allotment option.

In June 2013, Ocular secured additional financing.

In January 2013, Ocular raised \$23.8 million from a series D extension round of financing.

In February 2011, Ocular raised \$14 million from a series D financing round.

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Ocular disease	4	1	5
Inflammatory disease	2	0	2
Immune disorder	0	1	1
Neurological disease	1	0	1

[Return to Table of Contents](#)

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 3 Clinical	1
Phase 2 Clinical	1
Clinical	1
Discovery	1
No Development Reported	2

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Ocular disease	1	11
Inflammatory disease	1	5
Neurological disease	1	3
Surgical procedure	0	1

[Return to Table of Contents](#)

Trials by Phase

Phase	Ongoing	All
Phase 3	1	2
Phase 2	0	4
Phase 1	0	1
Phase not specified	0	4

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Ocular disease	0	1	1

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)



PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

dexamethasone (punctum plug, ocular inflammation/pain), Ocular Therapeutix

dexamethasone (punctum plug, ocular inflammation/pain), Ocular Therapeutix SNAPSHOT

Drug Name	dexamethasone (punctum plug, ocular inflammation/pain), Ocular Therapeutix
Key Synonyms	dexamethasone
Originator Company	Ocular Therapeutix Inc
Active Companies	Ocular Therapeutix Inc
Inactive Companies	
Highest Status	Phase 3 Clinical
Active Indications	Allergic conjunctivitis;Ocular inflammation;Ocular pain
Target-based Actions	Glucocorticoid agonist
Other Actions	Analgesic;Anti-inflammatory;Ophthalmological corticosteroid;Steroidal anti-inflammatory
Technologies	Sustained release formulation;Ophthalmic formulation;Ophthalmic drug implant;Small molecule therapeutic
Last Change Date	13-Nov-2014

dexamethasone (punctum plug, ocular inflammation/pain), Ocular Therapeutix DEVELOPMENT PROFILE

SUMMARY

Ocular Therapeutix is developing OTX-DP, a one-time, sustained-release, dexamethasone-loaded hydrogel punctum plug, for the potential intracanalicular treatment of post-operative ocular inflammation, pain and allergic conjunctivitis,.

In March 2014, a phase III trial was initiated for post-operative inflammation and pain. At that time, a second phase III trial was expected to start later in 2014. In October 2014, the company planned to submit results to the FDA in 2015. In March 2014, a phase II/III trial for allergic conjunctivitis was initiated ; in November 2014, results were reported. At that time, phase III results were expected in 1Q15 and an NDA was planned to be filed with the FDA in 2Q15.

dexamethasone (punctum plug, ocular inflammation/pain), Ocular Therapeutix DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Ocular Therapeutix Inc	Allergic conjunctivitis	US	Phase 3 Clinical	31-Mar-2014
Ocular Therapeutix Inc	Ocular inflammation	US	Phase 3 Clinical	17-Mar-2014


[Return to Table of Contents](#)



Company	Indication	Country	Development Status	Date
Ocular Therapeutix Inc	Ocular pain	US	Phase 3 Clinical	17-Mar-2014

dexamethasone (punctum plug, ocular inflammation/pain), Ocular Therapeutix CHEMICAL STRUCTURES

CAS Registry Number:	Confidence Level:
50-02-2	1





Name	Type
dexamethasone	BANN; INN
Surodex	Trade Name
Ozurdex	Trade Name
OTO-104	Research Code
TLC-x99	Research Code
EGP-437	Research Code
IBI-10090	Research Code
OTX-DP	Research Code
ISV-305	Research Code
CD-102	Research Code
Oncocort	

dexamethasone (punctum plug, ocular inflammation/pain), Ocular Therapeutix DRUG NAMES

Names	Type
OTX-DP	Research Code
dexamethasone (punctum plug, ocular inflammation/pain), Ocular Therapeutix	
dexamethasone	BANN, INN

[Return to Table of Contents](#)

dexamethasone (punctum plug, ocular inflammation/pain), Ocular Therapeutix SALES AND CHARTS



COMMENTARY

CONSENSUS SALES INFORMATION

Consensus forecast data for Ocular Therapeutix are presented.

REGIONAL DEVELOPMENT AND MARKETING RIGHTS

Ocular Therapeutix holds worldwide development and marketing rights.

dexamethasone (punctum plug, ocular inflammation/pain), Ocular Therapeutix CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Ocular inflammation											
0	0	1	2	0	1	0	0	0	0	1	3
Ocular pain											
0	0	1	2	0	1	0	0	0	0	1	3
Allergic conjunctivitis											
0	0	0	0	0	1	0	0	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	1	2	0	2	0	0	0	0	1	4

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

travoprost (sustained release/punctal plug delivery system, glaucoma), Ocular Therapeutix

travoprost (sustained release/punctal plug delivery system, glaucoma), Ocular Therapeutix SNAPSHOT

Drug Name	travoprost (sustained release/punctal plug delivery system, glaucoma), Ocular Therapeutix
Key Synonyms	travoprost
Originator Company	Ocular Therapeutix Inc
Active Companies	Ocular Therapeutix Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Glaucoma
Target-based Actions	Prostanoid receptor agonist
Other Actions	Antiglaucoma agent;PGF2 alpha agonist
Technologies	Lipid;Drug implant;Sustained release formulation;Microparticle formulation;Small molecule therapeutic;Ophthalmic gel formulation
Last Change Date	14-Nov-2014

travoprost (sustained release/punctal plug delivery system, glaucoma), Ocular Therapeutix DEVELOPMENT PROFILE

SUMMARY

Ocular Therapeutix is developing sustained-release formulations of travoprost, including OTX-TP, OTX-TP1 and OTX-TP2, delivered using the company's punctum plug delivery system, for the potential treatment of glaucoma,.

In May 2012, a feasibility study of OTX-TP1, a 30-day sustained-release formulation, was initiated in glaucoma patients ; in July 2012, data were reported. In August 2012, a pilot phase II trial was initiated using OTX-TP2, a 2-month sustained-release formulation; in October 2012, data were reported. In November 2014, patient enrollment was initiated in a phase IIb trial.

The company is also investigating the treatment as OTX-TP2, a 60-day sustained-release formulation of travoprost; at that time, phase II trials were expected later in 2012.

travoprost (sustained release/punctal plug delivery system, glaucoma), Ocular Therapeutix DEVELOPMENT STATUS


CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Ocular Therapeutix Inc	Glaucoma	South Africa	Phase 2 Clinical	20-Aug-2012
Ocular Therapeutix Inc	Glaucoma	Singapore	Clinical	04-May-2012

[Return to Table of Contents](#)



travoprost (sustained release/punctal plug delivery system, glaucoma), Ocular Therapeutix
CHEMICAL STRUCTURES




CAS Registry Number:	Confidence Level:
157283-68-6	1
	
Name	Type
travoprost	BANN; INN; USAN
Izba	Trade Name
Travatan	Trade Name
AL-6221	Research Code
GLT-137	Research Code

travoprost (sustained release/punctal plug delivery system, glaucoma), Ocular Therapeutix
DRUG NAMES

Names	Type
OTX-TP2	Research Code
travoprost	USAN, BANN, INN
travoprost (sustained release/punctal plug delivery system, glaucoma), Ocular Therapeutix	
OTX-TP	Research Code
prostaglandin (ophthalmic sustained release/punctal plug delivery system), Ocular Therapeutix	
OTX-TP1	Research Code

[Return to Table of Contents](#)

CHARTS



[Return to Table of Contents](#)

COMMENTARY

CONSENSUS SALES INFORMATION

Consensus forecast data for Ocular Therapeutix are presented.

REGIONAL DEVELOPMENT AND MARKETING RIGHTS

Ocular Therapeutix holds worldwide development and marketing rights.

travoprost (sustained release/punctal plug delivery system, glaucoma), Ocular Therapeutix CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Open angle glaucoma											
0	0	0	0	0	2	0	1	0	1	0	4
Ocular hypertension											
0	0	0	0	0	2	0	0	0	0	0	2

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	2	0	1	0	1	0	4

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

moxifloxacin (ophthalmic sustained release/punctal plug delivery system, bacterial conjunctivitis), Ocular Therapeutix

moxifloxacin (ophthalmic sustained release/punctal plug delivery system, bacterial conjunctivitis), Ocular Therapeutix SNAPSHOT

Drug Name	moxifloxacin (ophthalmic sustained release/punctal plug delivery system, bacterial conjunctivitis), Ocular Therapeutix
Key Synonyms	moxifloxacin
Originator Company	Ocular Therapeutix Inc
Active Companies	Ocular Therapeutix Inc
Inactive Companies	
Highest Status	Clinical
Active Indications	Conjunctivitis
Target-based Actions	DNA gyrase inhibitor;Topoisomerase IV inhibitor
Other Actions	Bacterial nucleic acid synthesis inhibitor;Ophthalmological antibacterial
Technologies	PEGylated formulation;Drug implant;Sustained release formulation;Antibiotic;Microparticle formulation;Small molecule therapeutic;Ophthalmic gel formulation
Last Change Date	05-Jun-2013

moxifloxacin (ophthalmic sustained release/punctal plug delivery system, bacterial conjunctivitis), Ocular Therapeutix DEVELOPMENT PROFILE

SUMMARY

Ocular Therapeutix is developing a sustained-release formulation of moxifloxacin, a PEG hyrogel rod comprising of free and poly (lactic-co-glycolic acid) encapsulated moxifloxacin particles, delivered using the company's punctum plug delivery system, for the potential treatment of bacterial conjunctivitis. In October 2010, positive clinical results were reported ; in May 2013, further clinical data were reported.


moxifloxacin (ophthalmic sustained release/punctal plug delivery system, bacterial conjunctivitis), Ocular Therapeutix DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Ocular Therapeutix Inc	Conjunctivitis	US	Clinical	12-Oct-2010

moxifloxacin (ophthalmic sustained release/punctal plug delivery system, bacterial conjunctivitis), Ocular Therapeutix CHEMICAL STRUCTURES

[Return to Table of Contents](#)

CAS Registry Number:	Confidence Level:
151096-09-2	1
	
Name	Type
moxifloxacin	BANN; INN
Avalox	Trade Name
Avelox	Trade Name

moxifloxacin (ophthalmic sustained release/punctal plug delivery system, bacterial conjunctivitis), Ocular Therapeutix DRUG NAMES

Names	Type
moxifloxacin	BANN, INN
moxifloxacin (ophthalmic sustained release/punctal plug delivery system, bacterial conjunctivitis), Ocular Therapeutix	

moxifloxacin (ophthalmic sustained release/punctal plug delivery system, bacterial conjunctivitis), Ocular Therapeutix CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Conjunctivitis											
0	0	0	0	0	0	0	0	0	1	0	1

[Return to Table of Contents](#)

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	0	0	1	0	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

anti-VEGF protein therapeutic (sustained release depot, retinal disease), Ocular Therapeutix

anti-VEGF protein therapeutic (sustained release depot, retinal disease), Ocular Therapeutix SNAPSHOT

Drug Name	anti-VEGF protein therapeutic (sustained release depot, retinal disease), Ocular Therapeutix
Key Synonyms	
Originator Company	Ocular Therapeutix Inc
Active Companies	Ocular Therapeutix Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Retinopathy
Target-based Actions	VEGF receptor antagonist
Other Actions	
Technologies	PEGylated formulation;Sustained release formulation;Ophthalmic formulation;Small molecule therapeutic;Peptide
Last Change Date	13-Nov-2014

anti-VEGF protein therapeutic (sustained release depot, retinal disease), Ocular Therapeutix DEVELOPMENT PROFILE

SUMMARY

Ocular Therapeutix is investigating a posterior segment sustained release depot formulation of an anti-VEGF protein therapeutic, delivered using PEG hydrogel technology, for the potential intravitreal treatment of back of the eye disease,. In January 2014, development was ongoing. In October 2014, the program was listed as being in preclinical development .

anti-VEGF protein therapeutic (sustained release depot, retinal disease), Ocular Therapeutix DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Ocular Therapeutix Inc	Retinopathy	US	Discovery	10-Jan-2014

anti-VEGF protein therapeutic (sustained release depot, retinal disease), Ocular Therapeutix DRUG NAMES

Names	Type
anti-VEGF protein therapeutic (sustained release depot, retinal disease), Ocular Therapeutix	

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

